In this podcast, Andre Alfaro, Director of Assay Development at nanoComposix, lends expertise to medical device manufacturers entering the LFT market, particularly for COVID-19. Andre provides insights into this fast-growing sector and explains how nanoComposix can help every step of the way. Timestamps: [0:44] - nanoComposix's lateral-flow development services  [3:50] - Developing a SARS-CoV-2 lateral-flow test and bringing it to market  [4:58] - The beauty of antibody tests [7:47] - Why choose nanoComposix? [9:50] - How precious are gold particles? [13:32] - Health product agencies raising the quality standards bar  [15:20] - 1st gen assays that gave the rapid test a bad rap [19:20] - How robust is your supply chain? [21:45] - We're on top of mutating viruses  [22:50] - Saliva-based tests are the way forward [25:34] - Lateral-flow can do it in 60 seconds [27:05] - ISO Standards [27:56] - Talking to experts enables proper planning